224 related articles for article (PubMed ID: 33535181)
41. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
[TBL] [Abstract][Full Text] [Related]
42. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD.
De Preter V; Machiels K; Joossens M; Arijs I; Matthys C; Vermeire S; Rutgeerts P; Verbeke K
Gut; 2015 Mar; 64(3):447-58. PubMed ID: 24811995
[TBL] [Abstract][Full Text] [Related]
43. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
44. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
46. Micro-RNAs -106a and -362-3p in Peripheral Blood of Inflammatory Bowel Disease Patients.
Omidbakhsh A; Saeedi M; Khoshnia M; Marjani A; Hakimi S
Open Biochem J; 2018; 12():78-86. PubMed ID: 30069249
[TBL] [Abstract][Full Text] [Related]
47. Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases.
Soubières AA; Poullis A
Inflamm Bowel Dis; 2016 Aug; 22(8):2016-22. PubMed ID: 27416044
[TBL] [Abstract][Full Text] [Related]
48. Sparse Modeling Reveals miRNA Signatures for Diagnostics of Inflammatory Bowel Disease.
Hübenthal M; Hemmrich-Stanisak G; Degenhardt F; Szymczak S; Du Z; Elsharawy A; Keller A; Schreiber S; Franke A
PLoS One; 2015; 10(10):e0140155. PubMed ID: 26466382
[TBL] [Abstract][Full Text] [Related]
49. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease.
Malham M; Lilje B; Houen G; Winther K; Andersen PS; Jakobsen C
Scand J Gastroenterol; 2019 Aug; 54(8):969-975. PubMed ID: 31329473
[No Abstract] [Full Text] [Related]
50. Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases - hallmark of epithelial-mesenchymal transition.
Zidar N; Boštjančič E; Jerala M; Kojc N; Drobne D; Štabuc B; Glavač D
J Cell Mol Med; 2016 Oct; 20(10):1813-20. PubMed ID: 27113480
[TBL] [Abstract][Full Text] [Related]
51. [Expression of microRNA-155 in inflammatory bowel disease and its clinical significance].
Ye YL; Pang Z; Gu W; Zheng JJ
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3716-3719. PubMed ID: 29325325
[No Abstract] [Full Text] [Related]
52. Mechanism underlying the significant role of the miR-4262/SIRT1 axis in children with inflammatory bowel disease.
Deng X; Shang L; Du M; Yuan L; Xiong L; Xie X
Exp Ther Med; 2020 Sep; 20(3):2227-2235. PubMed ID: 32765699
[TBL] [Abstract][Full Text] [Related]
53. Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis.
Basso D; Padoan A; D'Incà R; Arrigoni G; Scapellato ML; Contran N; Franchin C; Lorenzon G; Mescoli C; Moz S; Bozzato D; Rugge M; Plebani M
Clin Chem Lab Med; 2020 Jun; 58(6):968-979. PubMed ID: 32229654
[TBL] [Abstract][Full Text] [Related]
54. Relationship between fecal lactoferrin and inflammatory bowel disease.
Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
[TBL] [Abstract][Full Text] [Related]
55. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
Langhorst J; Boone J
Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
[TBL] [Abstract][Full Text] [Related]
56. Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis.
Lehmann T; Schallert K; Vilchez-Vargas R; Benndorf D; Püttker S; Sydor S; Schulz C; Bechmann L; Canbay A; Heidrich B; Reichl U; Link A; Heyer R
J Proteomics; 2019 Jun; 201():93-103. PubMed ID: 31009805
[TBL] [Abstract][Full Text] [Related]
57. Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles.
Chandradevan R; Hofmekler T; Mondal K; Harun N; Venkateswaran S; Somineni HK; Ballengee CR; Kim MO; Griffiths A; Noe JD; Crandall WV; Snapper S; Rabizadeh S; Rosh JR; Walters TD; Bertha M; Dubinsky MC; Denson LA; Sauer CG; Markowitz JF; LeLeiko NS; Hyams JS; Kugathasan S
Inflamm Bowel Dis; 2018 Sep; 24(10):2285-2290. PubMed ID: 29860529
[TBL] [Abstract][Full Text] [Related]
58. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.
Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K
Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038
[TBL] [Abstract][Full Text] [Related]
59. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
60. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease.
Aomatsu T; Imaeda H; Matsumoto K; Kimura E; Yoden A; Tamai H; Fujiyama Y; Mizoguchi E; Andoh A
Aliment Pharmacol Ther; 2011 Oct; 34(8):941-8. PubMed ID: 21848856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
